DEB vs Thin-DES in DES-ISR: Long Term Outcomes (DEB Dragon Registry)
NCT ID: NCT04415216
Last Updated: 2021-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1369 participants
OBSERVATIONAL
2019-10-10
2020-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Drug Eluting Balloon Versus Drug Eluting Stent in PCI
NCT01760200
Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )
NCT04119986
Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions
NCT04072081
Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With ST-Segment Elevation Myocardial Infarction
NCT06742125
Drug-coated Balloon Therapy for In-stent Restenosis and de Novo Coronary Lesions
NCT05552911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ISR PCI with thin-DES
percutaneous coronary intervention
Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
ISR PCI with DEB
percutaneous coronary intervention
Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
percutaneous coronary intervention
Percutaneous coronary intervention with drug eluting balloon (DEB) vs. thin struts drug eluting stents (thin-DES) for treating in-stent restenosis (ISR)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* PCI with DEB and thin-DES in the same procedure
* PCI of other vascular territories during the same procedure
* PCI in saphenous vain graft or internal mammary artery
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wojciech Wojakowski
UNKNOWN
Medical University of Silesia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wojciech Wańha
MD, PhD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Invasive Cardiology, Medical University of Bialystok
Bialystok, , Poland
Cardiovascular Institute, Nicolaus Copernicus University, Bydgoszcz, Poland
Bydgoszcz, , Poland
First Department of Cardiology, Medical University of Gdansk, Gdansk, Poland
Gdansk, , Poland
Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
Katowice, , Poland
Second Department of Cardiology, Jagiellonian University Medical College, Krakow, Poland
Krakow, , Poland
Department of Interventional Cardiology and Angiology, National Institute of Cardiology, Warsaw, Poland
Warsaw, , Poland
Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration
Warsaw, , Poland
Centre for Heart Disease, University Hospital Wroclaw Department of Heart Disease, Wroclaw Medical University
Wroclaw, , Poland
Third Department of Cardiology, Medical University of Katowice
Zabrze, , Poland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
De Filippo O, Wanha W, Sanavia T, Januszek R, Giacobbe F, Campo G, Pinxterhuis TH, Capodanno D, Tomasiewicz B, Iannaccone M, Leone A, Wolny R, Bruno F, Patti G, Musumeci G, Liccardo G, Verardi R, Roubin SR, Tarantini G, Kuzma L, Perl L, Gagnor A, Reczuch K, Conrotto F, Tuttolomondo D, Ploumen EH, Niezgoda P, Caglioni S, Omede P, Greco A, Kubica J, Gil RJ, Piccolo R, Kornowski R, Bil J, Morena A, Zocca P, Pennone M, Gasior M, Jaguszewski M, von Birgelen C, Fariselli P, De Ferrari GM, Wojakowski W, D'Ascenzo F. Treatment of in-stent restenosis with ultrathin-strut versus thin-strut drug-eluting stents or drug-eluting balloons: a multicentre registry. EuroIntervention. 2024 Nov 4;20(21):e1340-e1354. doi: 10.4244/EIJ-D-24-00491.
Wanha W, Bil J, Januszek R, Gilis-Malinowska N, Figatowski T, Milewski M, Pawlik A, Staszczak B, Wybraniec M, Tomasiewicz B, Kubler P, Kuliczkowski W, Walczak T, Hrymniak B, Desperak P, Mielczarek M, Ciecwierz D, Niezgoda P, Wolny R, Chudzik M, Kuzma L, Kralisz P, Kedhi E, D'Ascenzo F, Hudziak D, Kowalowka A, Smolka G, Reczuch K, Gruchala M, Kubica J, Gil RJ, Dobrzycki S, Dudek D, Bartus S, Gasior M, Ochala A, Witkowski A, Jaguszewski M, Wojakowski W. Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). Circ Cardiovasc Interv. 2021 Sep;14(9):e010868. doi: 10.1161/CIRCINTERVENTIONS.121.010868. Epub 2021 Sep 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.